Nyang'wa BT, Berry C, Kazounis E, Motta I, Parpieva N, et al.
2024-02-01 • Lancet Respiratory Medicine
2024-02-01 • Lancet Respiratory Medicine
BACKGROUND Around 500,000 people worldwide develop rifampicin-resistant tuberculosis each year. The proportion of successful treatment outcomes remains low and new treatments are nee...
du Cros PAK, Greig J, Cross GB, Cousins C, Berry C, et al.
2023-12-01 • International Journal of Tuberculosis and Lung Disease
2023-12-01 • International Journal of Tuberculosis and Lung Disease
BACKGROUND The value, speed of completion and robustness of the evidence generated by TB treatment trials could be improved by implementing standards for best practice.
METH...
Hayrapetyan A,
et al.
2015-02-01 • American Journal of Respiratory and Critical Care Medicine
2015-02-01 • American Journal of Respiratory and Critical Care Medicine
Swaminathan A, du Cros PAK, Seddon JA, Mirgayosieva S, Asladdin R, et al.
2017-06-12 • BMC Infectious Diseases
2017-06-12 • BMC Infectious Diseases
Extensively drug-resistant (XDR) tuberculosis (TB) and multidrug resistant (MDR)-TB with additional resistance to injectable agents or fluoroquinolones are challenging to treat due to la...
In 2011, Médecins Sans Frontières (MSF) established a blogging project, "TB&Me," to enable patients with multidrug-resistant tuberculosis (MDR-TB) to share their experiences. By Septembe...
Rao VB, Johari N, du Cros PAK, Messina J, Ford NP, et al.
2015-05-05 • Lancet Infectious Diseases
2015-05-05 • Lancet Infectious Diseases
An estimated 150 million people worldwide are infected with hepatitis C virus (HCV). HIV co-infection accelerates the progression of HCV and represents a major public health challenge. W...
Abidi S, Achar J, Assao Neino MM, Bang D, Benedetti A, et al.
2020-03-20 • European Respiratory Journal
2020-03-20 • European Respiratory Journal
We sought to compare the effectiveness of two World Health Organization (WHO)-recommended regimens for the treatment of rifampin- or multidrug-resistant (RR/MDR) tuberculosis (TB): a sta...
Swaminathan A, du Cros PAK, Achar J, Kliescikova J, Mirgayosieva S, et al.
2020-04-22 • BMC Infectious Diseases
2020-04-22 • BMC Infectious Diseases
Background: There are unique challenges in the diagnosis and management of multi drug resistant tuberculosis (MDR-TB) in children. It is difficult to obtain confirmatory microbiological ...
Truelove SA, Hedge S, Kostandova N, Niehaus L, Rao B, et al.
2021-05-18 • MSF Scientific Days International 2021: Research
2021-05-18 • MSF Scientific Days International 2021: Research
INTRODUCTION Since the emergence of the COVID-19 pandemic, concerns have arisen regarding the potential impact of outbreaks affecting Rohingya refugees living in the Kutupalong-Baluk...
Bastard M, Sanchez-Padilla E, du Cros PAK, Khamraev AK, Parpieva N, et al.
2018-03-08 • PLOS One
2018-03-08 • PLOS One
The emergence of resistance to anti-tuberculosis (DR-TB) drugs and the HIV epidemic represent a serious threat for reducing the global burden of TB. Although data on HIV-negative DR-TB t...
Sadique S, Lin YD, Walker SA, Rao B, du Cros PAK, et al.
2022-05-09 • MSF Scientific Days International 2022
2022-05-09 • MSF Scientific Days International 2022
INTRODUCTION The crowded conditions within camps for refugees and internally displaced people create risk environments for unmitigated transmission of SARS-CoV-2. Within one such set...
Greig J, du Cros PAK, Mills C, Ugwoeruchukwu W, Etsetowaghan A, et al.
2013-08-14 • PLOS One
2013-08-14 • PLOS One
OBJECTIVES In Lagos, Nigeria, Médecins Sans Frontières (MSF) and the Ministry of Health (MoH) commenced free antiretroviral treatment (ART) in a hospital-based clinic. We performed a...
